Discovery of novel N-β-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes.

A novel series of N-linked beta-D-xylosides were synthesized and evaluated for inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) in a cell-based assay Of these, the 4-chloro-3-(4-cyclopropylbenzyl)-1-(beta-D-xylopyranosyl)-1H-indole 19m was found to be the most potent Inhibitor, with an EC50 value similar to that of the natural SGLT2 inhibitor phlorizin Further studies in Sprague Dawley (SD) rats indicated that 19m significantly increased urine glucose excretion in a dose-dependent manner with oral administration The antihyperglycemic effect of 19m was also observed in streptozotocin (STZ) induced diabetic SD rats These results described here are a good starting point for further investigations into N-glycoside SGLT2 inhibitors